Economics of thromboprophylaxis in total hip replacement surgery

PharmacoEconomics

Volumn 12, Issue 1, 1997, Pages 30-41

  Harrison, Jeff ^a   Warwick, David J ^a   Coast, Joanna ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; DEXTRAN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; HEALTH CARE COST; HOSPITAL COST; HUMAN; LUNG EMBOLISM; MODEL; MORBIDITY; PHLEBOGRAPHY; PRIORITY JOURNAL; REVIEW; THROMBOEMBOLISM; TOTAL HIP PROSTHESIS; TREATMENT OUTCOME; VEIN THROMBOSIS;

EID: 0030743381     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199712010-00004     Document Type: Review

References (27)

1. Seagroatt V, Tan ST, Goldacre M, et al Elective total hip replacement: incidence, emergency readmission rate, and post-operative mortality. BMJ 1991; 303: 1431-5
2. Coleridge Smith PD. European workshop on the prevention of thromboembolism. Phlebography 1992; 7: 45-6
3. Clagett GP, Anderson FA, Heit J, et al. Prevention of venous thromboembolism. Chest 1995; 108: 312s-24s
4. Guyer RD, Booth RE, Rothman RH. The detection and prevention of pulmonary embolism in total hip replacement. J Bone Joint Surg Am 1982; 64A: 1040-4
5. Unwin AJ, Harries WJ, Jones JR. Current orthopaedic opinion on thromboprophylaxis in orthopaedic surgery: its use in routine total hip and knee arthroplasty. Ann R Coll Surg Engl 1995; 77: 351-4
6. Warwick D, Williams MH, Bannister GC. Death and thromboembolic disease after hip replacement. J Bone Joint Surg Br 1995; 77-B: 6-10
7. Patterson BM, Marchand R, Ranawat C. Complications of heparin therapy after total joint replacement. J Bone Joint Surg Am 1989; 71A: 1130-4
8. Maxwell P. Anticoagulant therapy. Medicine 1995; 23 (12): 533
9. UK Committee on Safety of Medicine. Heparin induced thrombocytopenia: current problems [editorial]. Curr Probl 1990; 28
10. Dahl OE, Andreassen G, Müller C, et al. The effect of prolonged thromboprophylaxis with dalteparin on the frequency of deep vein thrombosis and pulmonary embolism 35 days after hip replacement [abstract]. Thromb Haemost 1995; 73 (6): 1094
11. Oster G, Tuden RL, Colditz GA. A cost-effectiveness analysis of prophylaxis against deep vein thrombosis in major orthopaedic surgery. JAMA 1987; 257: 203-8
12. Drummond M, Ristides M, Davies L, et al. Economic evaluation of standard heparin and enoxaparin for prophylaxis against deep vein thrombosis in elective hip surgery. Br J Surg 1994; 81: 1742-6
13. Paiement GD, Wessinger SJ, Harris WH. Cost-effectiveness of prophylaxis in total hip replacement. Am J Surg 1991; 161: 519-24
14. Borris LC, Lassen MR, Jensen HP, et al. Perioperative thrombosis with low molecular weight heparins in elective orthopaedic surgery: clinical and economic considerations. Int J Clin Pharmacol Ther 1994; 32 (5): 262-8
15. Menzin J, Colditz GA, Regan MM, et al. Cost-effectiveness of enoxaparin vs low dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery. Arch Intern Med 1995; 155: 757-64
16. Lotke PA, Steinberg ME, Ecker ML. Significance of deep vein thrombosis in the lower extremity after total joint replacement. Clin Orthop 1994; 299: 25-30
17. Anderson DR, O'Brien BJ, Levine MN, et al. Efficacy and cost of low molecular weight heparin compared with standard heparin for the prevention of deep vein thrombosis after total hip arthroplasty. Ann Intern Med 1993; 119: 1105-12
18. Dalen JE, Alpert JS. Natural history of pulmonary embolism. Prog Cardiovasc Dis 1975; 17: 259-70
19. Drummond MF, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press, 1994
20. Health Economics Research Centre. A manual of standard costs for pharmacoeconomic studies in Canada: feasibility study. Edmonton: Health Economics Research Centre, 1995
21. Stamatakis JD, Kakkar V, Sagar S, et al. Femoral vein thrombosis and total hip replacement. BMJ 1977; 2: 223-5
22. Planes A, Vochelle N, Darmon JY, et al. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo. Lancet 1996; 348: 224-8
23. Menzin J, Richner R, Huse D, et al. Prevention of deep vein thrombosis following total hip replacement surgery with enoxaparin versus unfractionated heparin: a pharmacoeconomic evaluation. Ann Pharmacother 1994; 28: 271-5
24. Trowbridge A, Kent Boese C, Woodruff B, et al. Incidence of post-hospitalisation proximal deep vein thrombosis after total hip arthroplasty. Clin Orthop 1994; 299: 203-8
25. Salzman EW, Davies GC. Prophylaxis of venous thromboembolism. Ann Srug 1980; 191 (2): 207-18
26. O'Brien BJ, Anderson DR, Goeree R. Cost effectiveness of enoxaparin versus warfarin prophylaxis against deep vein thrombosis after total hip replacement. Can Med Assoc J 1994; 150 (7): 1083-1090
27. Murray DW, Britton AR, Bulstrode CJK. Thromboprophylaxis and death after total hip replacement. J Bone Joint Surg Br 1996; 78B: 863-70